Immuno Flashcards Preview

Pharma drugs > Immuno > Flashcards

Flashcards in Immuno Deck (24)
Loading flashcards...
1

Cyclosporine
[MOA, clinical use, Toxicity]

Calcineurin inhibitor (calcineurin activated by TCR of Th cells).
>Binds cyclophilin on Calcineurin -- prevents IL-2 transcription -- blocks T cell activation.
>For transplant rejection prophylaxis, psoriasis, RA.
>Nephrotoxic, neurotoxic

2

Tacrolimus (FK506)
[MOA, clinical use, toxicity]

Calcineurin inhibitor (calcineurin activated by TCR of Th cells).
>Binds FKBP on calcineurin -- prevents IL-2 transcription -- blocks T cell activation.
>For transplant rejection prophylaxis.
>Nephrotoxic, neurotoxic; Inc. risk of diabetes.

3

Sirolimus (Rapamycin)
[MOA, clinical use, toxicity]

mTOR inhibitor (mTOR activated by IL-2R).
>Binds FKBP on mTOR -- prevents RESPONSE to IL-2 -- blocks T cell activation, B cell differentiation.
>For kidney transplant rejection prophylaxis.
>Toxicity: Pancytopenia, insulin resistance.
*Synergistic w/ cyclosporine

4

Daclizumab, Basiliximab
[MOA, clinical use]

Monoclonal antibodies.
Block IL-2R -- prevents T cell proliferation.
For kidney transplant rejection prophylaxis

5

Azathioprine (6-MP metabolite)
[MOA, clinical use, toxicity]

>Blocks nucleotide synth (PRPP amidotransferase) -- inhibits lymphocyte proliferation.
>For transplant rejection prophylaxis, GN, Crohn dse, RA.
>Toxicity: Leukopenia, anemia, thrombocytopenia (6-MP degraded by xanthine oxidase, so toxicity inc. by allopurinol)

6

Glucocorticoids
[MOA, clinical use, toxicity]

>Inhibits NF-kB -- dec. cytokine transcription -- suppresses B/T cell function.
>For transplant rejection prophylaxis, autoimmune d/o, inflammation.
>Toxicity: hyperglycemia, obesity, osteoporosis; iatrogenic Cushing syndrome

7

IFN-alpha

Chronic hep B/C, Kaposi sarcoma, malignant melanoma

8

IFN-beta

Multiple sclerosis

9

IFN-gamma

Chronic granulomatous dse

10

Aldesleukin (IL-2)

Renal cell carcinoma, metastatic melanoma

11

Epoetin alfa

Anemias (esp. in renal failure)

12

Oprelvekin (IL-11)

Thrombocytopenia
*IL-11 induces megakaryocyte maturation -- platelet formation

13

Filgrastim (G-CSF)

Recovery of bone marrow

14

Alemtuzumab
[Target, clinical use]

Targets CD52 (all lymphocytes, monocytes).
For CLL

15

Bevacizumab
[Target, clinical use]

Targets VEGF.
Colorectal cancer, renal cell carcinoma

16

Cetuximab
[Target, clinical use]

Targets EGFR
Stage IV colorectal cancer
Head and neck cancer

17

Rituximab
[Target, clinical use]

Targets CD20 (B cells)
B cell NHL, CLL
Rheumatoid arthritis
ITP

18

Trastuzumab
[Target, clinical use]

Targets HER2/neu
Breast cancer

19

Eculizumab
[Target, clinical use]

Targets complement C5.
Paroxysmal nocturnal hemoglobinuria

20

Natalizumab
[Target, clinical use]

Targets alpha4-integrin (WBC adhesion).
Multiple sclerosis, Crohn dse

21

Adalimumab, Infliximab
[Target, clinical use]

Targets soluble TNF-alpha (monocloncal antibodies vs Etanercept decoy receptor).
IBD, psoriasis, Rheumatoid arthritis, ankylosing spondylitis.

22

Denosumab
[Target, clinical use]

Targets RANKL
Osteoporosis (inhibits osteoclast maturation; mimics osteoprotegrin)

23

Omalizumab
[Target, clinical use]

Targets IgE
Allergic asthma

24

Abciximab
[Target, clinical use]

Targets gpIIB/IIIa on platelets -- links platelets together for aggregation.
Antiplatelet agent to prevent ischemic cx in patients undergoing PCI.